Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2076 - 2100 of 14958 in total

Velmanase alfa

Velmanase alfa is a recombinant human lysosomal alpha-mannosidase developed for enzyme replacement therapy to treat alpha-mannosidosis. Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder. Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex...
Approved
Investigational
Matched Description: … Velmanase alfa has an amino acid sequence of the monomeric protein identical to the naturally occurring ... deterioration, such as skeletal abnormalities, motor function impairment, intellectual disability, and ... sugars in the body leads to an array of clinical manifestations leading to progressive neuromuscular and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Lifileucel

Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational
Matched Description: … suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Glymidine

Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta...
Approved
Investigational
Matched Description: … Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and ... appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and ... ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Hexamidine

Approved
Experimental
Matched Categories: … Biguanides and Amidines ... Antiseptics and Disinfectants ... Ophthalmological and Otological Preparations …

Zuranolone

Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptors. Unlike other more common GABAA positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and extrasynaptic GABAA conductance due to binding to a non-benzodiazepine site on the receptor.[A260776,A260786] Zuranolone was...
Approved
Experimental
Matched Description: … positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and ... [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved …
Matched Categories: … Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator …

Insulin degludec

Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid ... tissues such as the liver, fat cells, and skeletal muscle. ... inhibits lipolysis and proteolysis among many other functions. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin degludec and liraglutide ... insulin degludec and insulin aspart ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Cyclopenthiazide

Cyclopenthiazide is a thiazide diuretic with antihypertensive properties. In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients . It is a positive allosteric modulator at AMPA-A receptors .
Approved
Matched Categories: … cyclopenthiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... cyclopenthiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …

Sultamicillin

Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).
Approved
Investigational
Matched Description: … Pneumonia and Chronic Obstructive Pulmonary Disease (COPD). ... Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated …

Pentaerythritol tetranitrate

Pentaerythritol tetranitrate is the nitrate ester of pentaerythritol that possesses explosive properties. When mixed with a plasticizer, this chemical forms a plastic explosive. It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina . It is a pentaerythritol nitrate in...
Approved
Matched Description: … with nitric acid (HNO2). ... that is stored and shipped as a mixture with water and alcohol [L2394]. ... It is also one of the most powerful high explosives known and is a component of the plastic explosive …

Medrogestone

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn
Matched Description: … [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing …
Matched Categories: … medrogestone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …

Polistes annularis venom protein

Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Icatibant

Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B2 receptors antagonists, thus representing a new class of medication.[A4017,A263041] It was...
Approved
Investigational
Matched Description: … Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the Band has a potency of 2-3 times higher than ... [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Tremelimumab

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces ... investigated in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Hydrocortisone butyrate

Approved
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... hydrocortisone butyrate and antiseptics ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydrocortisone phosphate

Approved
Vet approved
Matched Iupac: … 3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}phosphonic acid …
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydrocortisone valerate

Approved
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Midazolam

Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by...
Approved
Illicit
Matched Description: … and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. ... This drug is unique from others in this class due to its rapid onset of effects and short duration of ... short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Perhexiline

Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
Approved
Investigational
Matched Description: … It may cause neuropathy and hepatitis. …
Matched Categories: … Calcium-Regulating Hormones and Agents …

Fingolimod

Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also...
Approved
Investigational
Matched Description: … neurological, physical, and cognitive effects. ... It was developed by Novartis and initially approved by the FDA in 2010. ... Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Vutrisiran

Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and mutant transthyretin (TTR) messenger RNA (mRNA). This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene. More than 130 TTR mutations have...
Approved
Investigational
Matched Description: … Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and ... [A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows ... prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Vosoritide

Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume and in length.[A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions, the...
Approved
Investigational
Matched Description: … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans ... missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and ... [A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lutetium Lu 177 dotatate

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as...
Approved
Investigational
Matched Description: … Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine ... tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver [A31697]. ... The presence of a radioligand allows monitoring of treatment response post therapy and prior to next …
Matched Categories: … Indicators and Reagents ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity ... results in the lysis of B-cells (both healthy and malignant). ... [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Bicisate

Bicisate, also known as ethyl cysteinate dimer (ECD), is a N,N'-1,2-ethylene-di-yl-bis-L-cysteinate diethyl ester. It is used in conjunction with technetium Tc99m as a tracer to measure cerebral blood flow with single-photon emission computed tomography (SPECT). The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl...
Approved
Investigational
Matched Description: … [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved …

Lanreotide

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen...
Approved
Matched Description: … It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. ... Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 2076 - 2100 of 14958 in total